OELKE MATHIAS 4

Accession 0001209191-23-023687

CIK 0001538210other

View on SEC.gov Company Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 8:41 PM ET

Size

46.4 KB

Accession

0001209191-23-023687

Insider Transaction Report

Form 4

Period: 2023-04-04

NexImmune, Inc.NEXI

OELKE MATHIAS

Chief Science Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2023-04-04−47,379→ 0 total
Exercise: $2.42Exp: 2027-03-02→ Common Stock (47,379 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−15,793→ 0 total
Exercise: $2.42Exp: 2027-03-02→ Common Stock (15,793 underlying)
Award
Stock Option (right to buy)
2023-04-04+4,755→ 4,755 total
Exercise: $1.23Exp: 2028-09-24→ Common Stock (4,755 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−115,051→ 0 total
Exercise: $2.58Exp: 2028-07-30→ Common Stock (115,051 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−60,000→ 0 total
Exercise: $4.22Exp: 2032-04-04→ Common Stock (60,000 underlying)
Award
Stock Option (right to buy)
2023-04-04+38,750→ 38,750 total
Exercise: $0.82Exp: 2032-04-04→ Common Stock (38,750 underlying)
Award
Stock Option (right to buy)
2023-04-04+81,100→ 81,100 total
Exercise: $0.41Exp: 2033-04-03→ Common Stock (81,100 underlying)
Award
Stock Option (right to buy)
2023-04-04+21,250→ 21,250 total
Exercise: $1.23Exp: 2032-04-04→ Common Stock (21,250 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−19,905→ 0 total
Exercise: $17.00Exp: 2031-02-10→ Common Stock (19,905 underlying)
Award
Stock Option (right to buy)
2023-04-04+7,050→ 7,050 total
Exercise: $0.82Exp: 2031-02-10→ Common Stock (7,050 underlying)
Award
Stock Option (right to buy)
2023-04-04+31,948→ 31,948 total
Exercise: $1.23Exp: 2029-03-18→ Common Stock (31,948 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−4,755→ 0 total
Exercise: $2.58Exp: 2028-09-24→ Common Stock (4,755 underlying)
Award
Stock Option (right to buy)
2023-04-04+15,793→ 15,793 total
Exercise: $1.23Exp: 2027-03-02→ Common Stock (15,793 underlying)
Award
Stock Option (right to buy)
2023-04-04+47,379→ 47,379 total
Exercise: $1.23Exp: 2027-03-02→ Common Stock (47,379 underlying)
Award
Stock Option (right to buy)
2023-04-04+12,855→ 12,855 total
Exercise: $1.23Exp: 2031-02-10→ Common Stock (12,855 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−31,948→ 0 total
Exercise: $4.31Exp: 2029-03-18→ Common Stock (31,948 underlying)
Award
Stock Option (right to buy)
2023-04-04+115,051→ 115,051 total
Exercise: $1.23Exp: 2028-07-30→ Common Stock (115,051 underlying)

Footnotes (7)

[F1]25% of this option shall vest and become exercisable on April 4, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Oelke's continued service to the corporation on each vesting date.
[F2]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 5, 2022, of which 15,000 shares vested, and the remainder of the options will vest in equal monthly installments such that on May 5, 2025, all shares subject to the option shall be vested, subject to Mr. Oelke's continued service on each vesting date.
[F3]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which 10,367 shares vested, and the remainder of the options will vest in equal monthly installments such that on February 11, 2025, all shares subject to the option shall be vested, subject to Mr. Oelke's continued service on each vesting date.
[F4]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested.
[F5]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on September 25, 2018, of which all of the shares subject to such option have vested.
[F6]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on July 31, 2021, of which all of the shares subject to such option have vested.
[F7]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested.

Documents

2 files

Issuer

NexImmune, Inc.

CIK 0001538210

→

Entity typeother

Related Parties

filerCIK 0001921607

Filing Metadata

Form type: 4
Filed: Apr 5, 8:00 PM ET
Accepted: Apr 6, 8:41 PM ET
Size: 46.4 KB

View on SEC.gov